Product Description
OPL-0301 is intended to address the disease state of post-myocardial infarction (MI) left ventricular dysfunction (LVD). MI is a manifestation of atherosclerotic coronary artery disease, the pathogenesis of which is closely associated with vascular and endothelial dysfunction, and inflammation. Acute MI leads to acute LVD, which often persists, leading to poor cardiovascular outcomes. The therapeutic hypothesis is that these effects mediated by Sphingosine-1 Phosphate 1 (S1P1) receptor agonism with OPL-0301 will reduce infarct size and benefit post-MI left ventricular function, thereby supporting improved cardiovascular outcomes in this patient population. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05327855)
Mechanisms of Action: S1P1 Agonist
Novel Mechanism: No
Modality: Unknown
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Valo Health
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Ventricular Dysfunction|Myocardial Infarction
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05327855 |
RESTORE | P2 |
Withdrawn |
Ventricular Dysfunction|Myocardial Infarction |
2024-08-01 |
2% |
2023-02-24 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|